KR20160018527A - Cmv 중화 항원 결합 단백질 - Google Patents

Cmv 중화 항원 결합 단백질 Download PDF

Info

Publication number
KR20160018527A
KR20160018527A KR1020157034735A KR20157034735A KR20160018527A KR 20160018527 A KR20160018527 A KR 20160018527A KR 1020157034735 A KR1020157034735 A KR 1020157034735A KR 20157034735 A KR20157034735 A KR 20157034735A KR 20160018527 A KR20160018527 A KR 20160018527A
Authority
KR
South Korea
Prior art keywords
seq
cdr2
cdr3
cdr1
gly
Prior art date
Application number
KR1020157034735A
Other languages
English (en)
Korean (ko)
Inventor
퉁-밍 푸
다이 왕
즈치앙 안
Original Assignee
머크 샤프 앤드 돔 코포레이션
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템, 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20160018527A publication Critical patent/KR20160018527A/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088Varicella-zoster virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089Cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
KR1020157034735A 2013-06-10 2014-06-09 Cmv 중화 항원 결합 단백질 KR20160018527A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833184P 2013-06-10 2013-06-10
US61/833,184 2013-06-10
PCT/US2014/041504 WO2014200898A2 (en) 2013-06-10 2014-06-09 Cmv neutralizing antigen binding proteins

Publications (1)

Publication Number Publication Date
KR20160018527A true KR20160018527A (ko) 2016-02-17

Family

ID=52022906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157034735A KR20160018527A (ko) 2013-06-10 2014-06-09 Cmv 중화 항원 결합 단백질

Country Status (11)

Country Link
US (1) US9868777B2 (ru)
EP (1) EP3008087A4 (ru)
JP (1) JP2016521711A (ru)
KR (1) KR20160018527A (ru)
CN (1) CN105579469A (ru)
AU (1) AU2014278481A1 (ru)
BR (1) BR112015030892A2 (ru)
CA (1) CA2912913A1 (ru)
MX (1) MX2015016978A (ru)
RU (1) RU2015155601A (ru)
WO (1) WO2014200898A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530402B (zh) 2015-03-06 2021-06-11 德克萨斯大学体系董事会 抗lilrb抗体及其在检测和治疗癌症中的用途
EP3313993A4 (en) * 2015-06-29 2019-06-19 Regents of the University of Minnesota ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
EP3445393A4 (en) * 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
WO2017196819A2 (en) 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof
JP2018203632A (ja) * 2017-05-30 2018-12-27 公益財団法人ヒューマンサイエンス振興財団 モノクローナル抗体及び測定キット
CA3067835A1 (en) * 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
CA3072261A1 (en) * 2017-08-24 2019-02-28 Phanes Therapeutics, Inc. Anti-apelin antibodies and uses thereof
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN113423732A (zh) * 2018-09-05 2021-09-21 德克萨斯大学系统董事会 针对endotrophin的单克隆抗体及其用途
US10666510B2 (en) 2018-10-30 2020-05-26 Bank Of America Corporation Conserving computing resources during network parallel processing
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361779B1 (en) * 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
RU2007139915A (ru) * 2005-03-30 2009-05-10 Новартис Вэксинес Энд Дайэгностикс Инк. (Us) Haemophilus influenzae типа в
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2011076883A1 (en) * 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
US9073990B2 (en) * 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
PE20140195A1 (es) * 2010-09-29 2014-02-24 Genentech Inc Composiciones de anticuerpo y metodos de uso
EP2710037B1 (en) * 2011-05-19 2019-07-31 The Regents of The University of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US20130039974A1 (en) * 2011-08-10 2013-02-14 Donald W. Kufe Anti-muc1 antibodies for cancer diagnostics
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製cmv

Also Published As

Publication number Publication date
RU2015155601A (ru) 2017-07-14
WO2014200898A3 (en) 2015-04-09
JP2016521711A (ja) 2016-07-25
WO2014200898A2 (en) 2014-12-18
US20160130327A1 (en) 2016-05-12
BR112015030892A2 (pt) 2017-08-29
EP3008087A4 (en) 2017-03-01
EP3008087A2 (en) 2016-04-20
AU2014278481A1 (en) 2015-12-03
MX2015016978A (es) 2016-04-25
US9868777B2 (en) 2018-01-16
CA2912913A1 (en) 2014-12-18
CN105579469A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
US9868777B2 (en) CMV neutralizing antigen binding proteins
US11981726B2 (en) Antibody neutralizing human respiratory syncytial virus
JP7045392B2 (ja) 抗ilt4抗体および抗原結合性フラグメント
JP2020528752A (ja) 抗sirp−アルファ抗体及び関連方法
KR102381237B1 (ko) 항체-사이토카인 생착된 단백질 및 면역 관련 장애를 위한 사용 방법
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
CN107406511B (zh) Pcsk9抗体、其抗原结合片段及其医药用途
US11958895B2 (en) Anti-influenza neuraminidase monoclonal antibodies and uses thereof
US11230591B2 (en) CMV neutralizing antigen binding proteins
RU2818586C2 (ru) Антитела против собачьего ctla-4
WO2023108117A2 (en) Engineered fc domains and engineered hcmv viral fc receptors
EA039222B1 (ru) Антитело, нейтрализующее респираторно-синцитиальный вирус человека
TW201215618A (en) Antibody compositions and methods of use

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid